Research Training in Pediatric Oncology

描述（由申请人提供）：这是一项新的培训资助支持申请，其任务只有一个：T32项目的目标是培养未来儿科肿瘤学基础和/或临床研究的学术领导者。减轻儿科人群的癌症负担需要在整个范围内进行必要的研究，从基础分子和细胞生物学研究到转化工作，弥合基础研究和临床医学与临床研究之间的鸿沟。减轻儿科人群的癌症负担需要对学术儿科医生进行广泛而深入的培训。一群经验丰富、成就卓著的教师，包括达纳法伯癌症研究所（DFCI）儿科肿瘤科的教师，波士顿儿童医院（CHB）儿科血液学/肿瘤科的教师，以及哈佛医学院的其他组成部分，组成了这个项目的培训教师。该学院包括基础研究、转化研究和临床研究。学员将从DFCI-CHB儿童血液学/肿瘤学联合奖学金项目中选择。特别强调的是在选择导师和在研究期间进行监督时对受训者进行密切指导。该项目致力于发现和支持最有前途的研究员，包括少数族裔候选人。在过去的40年里，DFCI-CHB奖学金项目已经培训了1,200人，其中许多人是儿科医学的领导者和学者。拟议的T32计划将确保奖学金计划的延续和进一步发展，并承诺为癌症儿童的管理做出不可估量的贡献。

DESCRIPTION (provided by applicant): This is a new application for training grant support with a single mission: the goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research. Reducing the burden of cancer in the pediatric population requires necessitates research across the entire spectrum from fundamental molecular and cellular biologic studies to translational work that bridges the gulf that separates basic research and clinical medicine to clinical investigation. Reducing the burden of cancer in pediatric populations requires broad and intensive training of academic pediatric physicians. An experienced and highly accomplished group of faculty including faculty of the Department of Pediatric Oncology at the Dana Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Children's Hospital Boston (CHB), and additional components of the Harvard Medical School constitute the training faculty for this program. This faculty encompasses basic, translational, and clinical investigation. Trainees will be selected from the combined DFCI-CHB pediatric hematology/oncology fellowship program. Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 40 years the DFCI-CHB fellowship program has trained >200 individuals, many of whom are leaders and academic pediatric medicine. The proposed T32 program will ensure the continuance and further development of the fellowship program, and promises to contribute immeasurably to the management of children with cancer. While great strides have been made in diagnosis and treatment of pediatric cancers, much remains to be done. Cure of patients is often achieved with unacceptable side-effects, and for many solid tumors current therapy is inadequate. The best hope for reducing the burden of pediatric cancer is the training of committed researchers by an experienced and accomplished faculty that is involved in diverse aspects of basic and clinical research directly relevant to tackling these challenging problems in children.